Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases

Metastatic Progression of Prostate Cancer and E-Cadherin

(2011) Aaron P. Putzke et al.   AMERICAN JOURNAL OF PATHOLOGY

Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity

(2011) Rachel M.A. Barrett et al.   CELL CYCLE

PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

(2011) T. L. Lotan et al.   CLINICAL CANCER RESEARCH

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

(2011) J. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

(2011) Ingrid E. Wertz et al.   NATURE

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases

(2011) Xiaotun Zhang et al.   PLoS One

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers

(2011) A. Kumar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells

(2010) Shumin Zhang et al.   Molecular Cancer

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

(2009) Wennuan Liu et al.   NATURE MEDICINE

Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer

(2008) D. J. Brennan et al.   CLINICAL CANCER RESEARCH

Bcl-2 family proteins and cancer

(2008) K W Yip et al.   ONCOGENE